| Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline M Fleseriu, IA Hashim, N Karavitaki, S Melmed, MH Murad, R Salvatori, ... The Journal of Clinical Endocrinology & Metabolism 101 (11), 3888-3921, 2016 | 864 | 2016 |
| Consensus on diagnosis and management of Cushing's disease: a guideline update M Fleseriu, R Auchus, I Bancos, A Ben-Shlomo, J Bertherat, NR Biermasz, ... The lancet Diabetes & endocrinology 9 (12), 847-875, 2021 | 546 | 2021 |
| Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome M Fleseriu, BMK Biller, JW Findling, ME Molitch, DE Schteingart, C Gross, ... The Journal of Clinical Endocrinology & Metabolism 97 (6), 2039-2049, 2012 | 515 | 2012 |
| Pasireotide versus octreotide in acromegaly: a head-to-head superiority study A Colao, MD Bronstein, P Freda, F Gu, CC Shen, M Gadelha, M Fleseriu, ... The Journal of Clinical Endocrinology & Metabolism 99 (3), 791-799, 2014 | 463 | 2014 |
| Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial MR Gadelha, MD Bronstein, T Brue, M Coculescu, M Fleseriu, ... The lancet Diabetes & endocrinology 2 (11), 875-884, 2014 | 407 | 2014 |
| Systemic complications of acromegaly and the impact of the current treatment landscape: an update MR Gadelha, L Kasuki, DST Lim, M Fleseriu Endocrine reviews 40 (1), 268-332, 2019 | 342 | 2019 |
| Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes T Dillard, CG Yedinak, J Alumkal, M Fleseriu Pituitary 13, 29-38, 2010 | 333 | 2010 |
| A consensus on the diagnosis and treatment of acromegaly comorbidities: an update A Giustina, A Barkan, A Beckers, N Biermasz, BMK Biller, C Boguszewski, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e937-e946, 2020 | 321 | 2020 |
| Multidisciplinary management of acromegaly: a consensus A Giustina, G Barkhoudarian, A Beckers, A Ben-Shlomo, N Biermasz, ... Reviews in Endocrine and Metabolic Disorders 21, 667-678, 2020 | 294 | 2020 |
| A Pituitary Society update to acromegaly management guidelines M Fleseriu, BMK Biller, PU Freda, MR Gadelha, A Giustina, L Katznelson, ... Pituitary 24, 1-13, 2021 | 275 | 2021 |
| Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement FF Casanueva, AL Barkan, M Buchfelder, A Klibanski, ER Laws, ... Pituitary 20, 489-498, 2017 | 269 | 2017 |
| LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study X Bertagna, R Pivonello, M Fleseriu, Y Zhang, P Robinson, A Taylor, ... The Journal of Clinical Endocrinology & Metabolism 99 (4), 1375-1383, 2014 | 196 | 2014 |
| Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase R Pivonello, M Fleseriu, J Newell-Price, X Bertagna, J Findling, ... The Lancet Diabetes & Endocrinology 8 (9), 748-761, 2020 | 177 | 2020 |
| Somatostatin receptor ligands and resistance to treatment in pituitary adenomas D Cuevas-Ramos, M Fleseriu Journal of molecular endocrinology 52 (3), R223-R240, 2014 | 172 | 2014 |
| Clinical biology of the pituitary adenoma S Melmed, UB Kaiser, MB Lopes, J Bertherat, LV Syro, G Raverot, ... Endocrine reviews 43 (6), 1003-1037, 2022 | 169 | 2022 |
| Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center … J Brzana, CG Yedinak, SH Gultekin, JB Delashaw, M Fleseriu Pituitary 16, 490-498, 2013 | 164 | 2013 |
| Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial A Lacroix, F Gu, W Gallardo, R Pivonello, Y Yu, P Witek, M Boscaro, ... The lancet Diabetes & endocrinology 6 (1), 17-26, 2018 | 156 | 2018 |
| Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease M Fleseriu, R Pivonello, J Young, AH Hamrahian, ME Molitch, C Shimizu, ... Pituitary 19, 138-148, 2016 | 151 | 2016 |
| Challenges and pitfalls in the diagnosis of hyperprolactinemia L Vilar, M Fleseriu, MD Bronstein Arquivos Brasileiros de Endocrinologia & Metabologia 58, 9-22, 2014 | 131 | 2014 |
| Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement S Petersenn, M Fleseriu, FF Casanueva, A Giustina, N Biermasz, ... Nature Reviews Endocrinology 19 (12), 722-740, 2023 | 122 | 2023 |